Form D · Biotechnology
PHOTOPHARMICS INC
Lehi, UT · CIK 0001561150
Offering snapshot reported Nov 3, 2025 · SEC filing
- Reported sold
- $26.2M Offering amount: $26.3M
- Investors reported
- 47 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 31, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$23,883,208 → $26,195,278
- Reported investors27 → 47
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 3, 2025 | Amendment | $26,195,278 | $2,312,070vs Apr 18, 2025 | 47 | SEC filing |
| Apr 18, 2025 | Amendment | $23,883,208 | $7,773,417vs Nov 1, 2023 | 27 | SEC filing |
| Nov 1, 2023 | Initial | $16,109,791 | No comparison | 24 | SEC filing |
| Dec 11, 2020 | Initial | $2,500,000 | No comparison | 9 | SEC filing |
| Oct 11, 2019 | Initial | $6,644,601 | No comparison | 24 | SEC filing |
| Mar 7, 2017 | Initial | $2,650,566 | No comparison | 18 | SEC filing |
| Feb 10, 2017 | Initial | $2,327,991 | No comparison | 15 | SEC filing |
| Jul 16, 2015 | Initial | $2,060,000 | No comparison | 15 | SEC filing |
| Jan 8, 2013 | Initial | $2,079,992 | No comparison | 13 | SEC filing |
| Nov 14, 2012 | Initial | $330,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-496258
Source: Form D, filed Nov 3, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Adams | Director |
| Gavin Christensen | Director |
| Kent Savage | Director, Executive |
| Henry, Jr. Savage | Director, Executive |
| Ted Stanley | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3451 North Triumph Blvd Suite 201
Lehi, UT, 84043
Lehi, UT, 84043